Teladoc Health, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Teladoc Health announces its 2026 Annual Meeting of Stockholders, detailing director nominations, executive compensation vote, and auditor ratification.
NYSE
DEFA14A: Teladoc Health Urges Stockholders to Approve Executive Compensation and Incentive Award Plan
Teladoc Health is soliciting stockholder votes for the approval of executive compensation (Say-on-Pay Proposal) and an amendment to the 2023 Incentive Award Plan at the upcoming Annual Meeting on May 22, 2025.
NYSE
Teladoc Health, Inc. has filed a definitive proxy statement with the SEC.
NYSE
Teladoc Health is asking stockholders to approve an amendment to its 2023 Incentive Award Plan to increase the number of shares available for issuance by 6,850,000 shares, aiming to attract, motivate, and retain qualified personnel.
NYSE
Teladoc Health will hold its annual stockholder meeting on May 23, 2024, and has made proxy materials available for review.
NYSE
Teladoc Health's upcoming annual meeting will address director elections, executive compensation, auditor ratification, and other corporate matters.